pandel® (hydrocortisone probutate cream) Cream, 0.1%
Pandel Cream contains hydrocortisone probutate, a synthetic adrenocorticosteroid, for dermatologic use. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents.
Pandel (hydrocortisone probutate cream) Cream, 0.1% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.
Published Studies Related to Pandel (Hydrocortisone)
Continuous Subcutaneous Hydrocortisone Infusion Therapy in Addison's Disease: A
Randomized, Placebo-Controlled Clinical Trial. 
CONCLUSIONS: Biochemical measurements indicate similar cortisol exposure during
Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in
children: a randomized clinical trial. 
IMPORTANCE: Alopecia areata is an idiopathic cause of hair loss with limited
therapeutic repertoire. OBJECTIVE: To compare the efficacy and safety of a high- vs low-potency topical
corticosteroid in pediatric patients...
Randomized, double-blind, split-side, comparison study of moisturizer containing
licochalcone A and 1% hydrocortisone in the treatment of childhood atopic
CONCLUSION: Lic A had a similar result in terms of SCORAD compared to 1%
Randomized, double-blind, split-side comparison study of moisturizer containing
licochalcone vs. 1% hydrocortisone in the treatment of infantile seborrhoeic
hydrocortisone for the treatment of ISD... CONCLUSION: Moisturizer containing 0.025% licochalcone had higher cure rate
Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. [2011.11.17]
BACKGROUND: Tacrolimus is a topical calcineurin inhibitor with immunomodulatory, anti-inflammatory, and fungicidal properties that may be beneficial in the treatment of facial seborrheic dermatitis. OBJECTIVES: We sought to compare the efficacy and safety of tacrolimus with standard corticosteroid treatment in adults with facial seborrheic dermatitis in a phase II, single-blind, randomized controlled trial... CONCLUSION: Tacrolimus 0.1% ointment required significantly fewer applications compared with hydrocortisone 1% ointment to achieve a comparable clinical response in adults with facial seborrheic dermatitis. Tacrolimus was generally well tolerated. Copyright (c) 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
Clinical Trials Related to Pandel (Hydrocortisone)
Adherence to Topical Hydrocortisone 17-Butyrate 0.1% (LocoidŽ) Using Different Vehicles in Adults With Atopic Dermatitis [Active, not recruiting]
The purpose of this research study is to better understand how the study drug Locoid works
when people use it to treat atopic dermatitis.
Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC) [Recruiting]
Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency [Not yet recruiting]
Patients with chronic adrenal insufficiency need to adapt their hydrocortisone replacement
dose in conditions of physical or psychological stress to prevent life threatening adrenal
crisis. In cases of more severe impairment or unsecure gastrointestinal absorption (e. g.
gastroenteritis, severe infectious disease), parenteral administration of the hydrocortisone
dose is crucial. The study is conducted to offer patients the possibility to perform
hydrocortisone self administration in emergency situations in a way of administration which
is easy to perform and accepted by the patient. Therefore, pharmacokinetics and safety of
subcutaneous hydrocortisone administration will be studied and compared to intramuscular
Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD) [Recruiting]
Developing novel and effective pharmacologic interventions for this post-traumatic stress
disorder is important. The investigators propose to replicate findings of an earlier
published pilot study using low dose hydrocortisone as a treatment for PTSD. In order to do
so in a more meaningful way, the investigators will conduct a larger but similar randomized
double-blind placebo-controlled, cross-over design treatment study examining the use of low
dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from PTSD.
The investigators hypothesize that, as described by Aerni et al. (2004), administration of
daily hydrocortisone will lead to a reduction in PTSD symptom severity, but particularly for
re-experiencing types (e. g., flashbacks, nightmares)of symptoms. The investigators also hope
to examine potential predictors and moderators of treatment response based on subjects'
clinical characteristics, as well as serum cortisol and ACTH levels.
Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT) [Recruiting]
The aim of this study is to investigate whether a physiologically low hydrocortisone (HC)
dose is better for cognition as compared to a physiologically high HC dose. In addition,
quality of life, metabolic profile and somatosensation will be described in relation to HC